339.66
-11.04 (-3.15%)
| Previous Close | 350.70 |
| Open | 357.81 |
| Volume | 329,131 |
| Avg. Volume (3M) | 345,684 |
| Market Cap | 7,408,120,320 |
| Price / Sales | 91.48 |
| Price / Book | 9.51 |
| 52 Weeks Range | |
| Earnings Date | 31 Oct 2024 |
| Operating Margin (TTM) | -187.06% |
| Diluted EPS (TTM) | -25.05 |
| Total Debt/Equity (MRQ) | 15.33% |
| Current Ratio (MRQ) | 5.98 |
| Operating Cash Flow (TTM) | -431.02 M |
| Levered Free Cash Flow (TTM) | -263.11 M |
| Return on Assets (TTM) | -52.25% |
| Return on Equity (TTM) | -129.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Madrigal Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.25 |
|
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 8.56% |
| % Held by Institutions | 105.84% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 441.00 (UBS, 29.84%) | Buy |
| Median | 400.00 (17.77%) | |
| Low | 236.00 (B. Riley Securities, -30.52%) | Hold |
| Average | 370.80 (9.17%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 300.46 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 14 Jan 2025 | 400.00 (17.76%) | Buy | 303.71 |
| 22 Oct 2024 | 390.00 (14.82%) | Buy | 203.59 | |
| JMP Securities | 10 Jan 2025 | 427.00 (25.71%) | Buy | 338.91 |
| B. Riley Securities | 05 Nov 2024 | 236.00 (-30.52%) | Hold | 337.61 |
| UBS | 01 Nov 2024 | 441.00 (29.84%) | Buy | 319.58 |
| Oppenheimer | 23 Oct 2024 | 350.00 (3.04%) | Buy | 202.48 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Jan 2025 | Announcement | Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra |
| 03 Jan 2025 | Announcement | Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 06 Nov 2024 | Announcement | Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences |
| 31 Oct 2024 | Announcement | Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates |
| 30 Oct 2024 | Announcement | Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting® |
| 21 Oct 2024 | Announcement | Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis |
| 18 Oct 2024 | Announcement | Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |